Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants-Reference-Cited by-同舟云学术

Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants

Published:2022-03-11 Issue:3 Volume:5 Page:e221947
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Puia-Dumitrescu Mihai¹,Wood Thomas R.¹,Comstock Bryan A.²,Law Janessa B.¹,German Kendell¹,Perez Krystle M.¹,Gogcu Semsa³,Mayock Dennis E.¹,Heagerty Patrick J.²,Juul Sandra E.¹,Wadhawan Rajan⁴,Courtney Sherry E⁴,Robinson Tonya⁴,Ahmad Kaashif A⁴,Bendel-Stenzel Ellen⁴,Baserga Mariana⁴,LaGamma Edmund F⁴,Downey L Corbin⁴,Rao Raghavendra⁴,Fahim Nancy⁴,Lampland Andrea⁴,Frantz Ivan D⁴,Khan Janine⁴,Weiss Michael⁴,Gilmore Maureen M⁴,Ohls Robin K⁴,Lowe Jean⁴,Srinivasan Nishant⁴,Perez Jorge E⁴,McKay Victor⁴,

Affiliation:

1. Division of Neonatology, Department of Pediatrics, University of Washington, Seattle

2. Department of Biostatistics, University of Washington, Seattle

3. Division of Neonatology, Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina

4. for the Preterm Erythropoietin Neuroprotection (PENUT) Trial Consortium

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2789922/puiadumitrescu_2022_oi_220087_1646412804.34347.pdf

Reference45 articles.